Wall Street analysts expect that Genomic Health, Inc. (NASDAQ:GHDX) will announce earnings per share (EPS) of $0.09 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Genomic Health’s earnings, with the lowest EPS estimate coming in at $0.07 and the highest estimate coming in at $0.13. Genomic Health posted earnings per share of $0.04 during the same quarter last year, which would indicate a positive year-over-year growth rate of 125%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 20th.
On average, analysts expect that Genomic Health will report full-year earnings of ($0.09) per share for the current year, with EPS estimates ranging from ($0.15) to ($0.04). For the next financial year, analysts forecast that the company will post earnings of $0.34 per share, with EPS estimates ranging from $0.25 to $0.52. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Genomic Health.
A number of equities research analysts have recently commented on the stock. ValuEngine cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 19th. William Blair cut shares of Genomic Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, JPMorgan Chase & Co. cut shares of Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price objective on the stock. in a research note on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $32.33.
A number of institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new stake in Genomic Health in the 4th quarter valued at $301,000. Cornerstone Capital Management Holdings LLC. grew its stake in Genomic Health by 67.9% in the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 27,437 shares of the medical research company’s stock valued at $937,000 after acquiring an additional 11,100 shares during the period. Teachers Advisors LLC grew its stake in Genomic Health by 12.3% in the 4th quarter. Teachers Advisors LLC now owns 39,510 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 4,333 shares during the period. York Capital Management Global Advisors LLC acquired a new stake in Genomic Health in the 4th quarter valued at $423,000. Finally, Deutsche Bank AG grew its stake in Genomic Health by 53.4% in the 4th quarter. Deutsche Bank AG now owns 48,523 shares of the medical research company’s stock valued at $1,656,000 after acquiring an additional 16,883 shares during the period. 90.20% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Genomic Health (GHDX) opened at $32.91 on Tuesday. The company has a market cap of $1,140.00, a P/E ratio of -253.15 and a beta of 0.59. Genomic Health has a one year low of $26.54 and a one year high of $37.50.
ILLEGAL ACTIVITY NOTICE: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://stocknewstimes.com/2018/03/14/1413961.html.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.